RSS   Newsletter   Contact   Advertise with us
Post Online Media

Curis appoints Lori Kunkel to its board

Lori A. KunkelCuris, Inc., a biotechnology company, announced the appointment of Lori A. Kunkel to its board of directors.

Dr. Kunkel currently serves on the Board of Directors at Loxo Oncology, where she was formerly Acting Chief Medical Officer.

Article continues below

READ MORE Curis adds Marc Rubin to the board of directors

Prior to Loxo Oncology, Dr. Kunkel served as Chief Medical Officer at Pharmacyclics, Inc. leading integrated clinical development highlighted by the approval of Imbruvica.

She has also served as Chief Medical Officer at Proteolix Inc. (acquired by Onyx), Syndax, and ACT Biotech.

Prior to joining the biotechnology industry in 1995, Dr. Kunkel spent ten years in academic/clinical medicine and served as a faculty member in the Division of Hematology/Oncology's Bone Marrow Transplant Unit at University of California, Los Angeles.

She trained in internal medicine at Baylor College of Medicine, hematology at USC and oncology at UCLA, earning board certifications in these specialties.


 LATEST MOVES FROM Massachusetts 


 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy